Literature DB >> 24301677

SMN-dependent intrinsic defects in Schwann cells in mouse models of spinal muscular atrophy.

Gillian Hunter1, Arwin Aghamaleky Sarvestany, Sarah L Roche, Rebecca C Symes, Thomas H Gillingwater.   

Abstract

Low levels of survival of motor neuron (SMN) protein lead to spinal muscular atrophy (SMA). The major pathological hallmark of SMA is a loss of lower motor neurons from spinal cord and peripheral nerve. However, recent studies have revealed pathological changes in other cells and tissues of the neuromuscular system. Here, we demonstrate intrinsic, SMN-dependent defects in Schwann cells in SMA. Myelination in intercostal nerves was perturbed at early- and late-symptomatic stages of disease in two mouse models of SMA. Similarly, maturation of axo-glial interactions at paranodes was disrupted in SMA mice. In contrast, myelination of motor axons in the corticospinal tract of the spinal cord occurred normally. Schwann cells isolated from SMA mice had significantly reduced levels of SMN and failed to express key myelin proteins following differentiation, likely due to perturbations in protein translation and/or stability rather than transcriptional defects. Myelin protein expression was restored in SMA Schwann cells following transfection with an SMN construct. Co-cultures of healthy neurons with diseased Schwann cells revealed deficient myelination, suggestive of intrinsic defects in Schwann cells, as well as reduced neurite stability. Alongside myelination defects, SMA Schwann cells failed to express normal levels of key extracellular matrix proteins, including laminin α2. We conclude that Schwann cells require high levels of SMN protein for their normal development and function in vivo, with reduced levels of SMN resulting in myelination defects, delayed maturation of axo-glial interactions and abnormal composition of extracellular matrix in peripheral nerve.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24301677     DOI: 10.1093/hmg/ddt612

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  37 in total

1.  Defects in Motoneuron-Astrocyte Interactions in Spinal Muscular Atrophy.

Authors:  Chunyi Zhou; Zhihua Feng; Chien-Ping Ko
Journal:  J Neurosci       Date:  2016-02-24       Impact factor: 6.167

Review 2.  Developing therapies for spinal muscular atrophy.

Authors:  Mary H Wertz; Mustafa Sahin
Journal:  Ann N Y Acad Sci       Date:  2015-07-14       Impact factor: 5.691

3.  SMN deficiency negatively impacts red pulp macrophages and spleen development in mouse models of spinal muscular atrophy.

Authors:  Marie-Therese Khairallah; Jacob Astroski; Sarah K Custer; Elliot J Androphy; Craig L Franklin; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2017-03-01       Impact factor: 6.150

Review 4.  Advances in therapy for spinal muscular atrophy: promises and challenges.

Authors:  Ewout J N Groen; Kevin Talbot; Thomas H Gillingwater
Journal:  Nat Rev Neurol       Date:  2018-02-09       Impact factor: 42.937

5.  Selective vulnerability in neuronal populations in nmd/SMARD1 mice.

Authors:  Eric Villalón; Monir Shababi; Rachel Kline; Zachary C Lorson; Kyra M Florea; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2018-02-15       Impact factor: 6.150

Review 6.  Advances in modeling and treating spinal muscular atrophy.

Authors:  Meaghan Van Alstyne; Livio Pellizzoni
Journal:  Curr Opin Neurol       Date:  2016-10       Impact factor: 5.710

7.  Effects of Astroglia on Motor Neurons in Spinal Muscular Atrophy.

Authors:  Bert M Verheijen
Journal:  J Neurosci       Date:  2017-09-06       Impact factor: 6.167

8.  Motoneuron development influences dorsal root ganglia survival and Schwann cell development in a vertebrate model of spinal muscular atrophy.

Authors:  Le Thi Hao; Phan Q Duy; James D Jontes; Christine E Beattie
Journal:  Hum Mol Genet       Date:  2014-09-01       Impact factor: 6.150

Review 9.  Is spinal muscular atrophy a disease of the motor neurons only: pathogenesis and therapeutic implications?

Authors:  Chiara Simone; Agnese Ramirez; Monica Bucchia; Paola Rinchetti; Hardy Rideout; Dimitra Papadimitriou; Diane B Re; Stefania Corti
Journal:  Cell Mol Life Sci       Date:  2015-12-18       Impact factor: 9.261

10.  SMN-targeted therapeutics for spinal muscular atrophy: are we SMArt enough yet?

Authors:  Kathryn J Swoboda
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.